Multidrug resistance due to reduced drug accumulation is a phenomenon predominantly caused by the overexpression of members of the ATP-binding cassette (ABC) transporters, including ABCB1 (P-glycoprotein), ABCG2, and several ABCC family members [multidrug resistanceassociated protein (MRP)]. We previously reported that a thiosemicarbazone derivative, NSC73306, is cytotoxic to carcinoma cells that overexpress functional P-glycoprotein, and it resensitizes these cells to chemotherapeutics. In this study, we investigated the effect of NSC73306 on cells overexpressing other ABC drug transporters, including ABCG2, MRP1, MRP4, and MRP5. Our findings showed that NSC73306 is not more toxic to cells that overexpress these transporters compared with their respective parental cells, and these transporters do not confer resistance to NSC73306 either. In spite of this, we observed that NSC73306 is a transport substrate for ABCG2 that can effectively inhibit ABCG2-mediated drug transport and reverse resistance to both mitoxantrone and topotecan in ABCG2-expressing cells. Interactions between NSC73306 and the ABCG2 drug-binding site(s) were confirmed by its stimulatory effect on ATPase activity (140 -150 nmol/L concentration required for 50% stimulation) and by inhibition of [ 125 I]iodoarylazidoprazosin photolabeling (50% inhibition at 250 -400 nmol/L) of the substrate-binding site(s). Overall, NSC73306 seems to be a potent modulator of ABCG2 that does not interact with MRP1, MRP4, or MRP5. Collectively, these data suggest that NSC73306 can potentially be used, due to its dual mode of action, as an effective agent to overcome drug resistance by eliminating P-glycoprotein -overexpressing cells and by acting as a potent modulator that resensitizes ABCG2-expressing cancer cells to chemotherapeutics.
Introduction
Multidrug resistance (MDR) due to reduced drug accumulation is a phenomenon associated with the overexpression of ATP-binding cassette (ABC) transporters, such as P-glycoprotein (ABCB1), MDR-associated proteins (MRP), and ABCG2 or mitoxantrone resistance-associated protein.
These transporters have great clinical significance, given that they can actively efflux a structurally diverse range of chemotherapeutic agents with overlapping specificity (1, 2) . ABCG2, also known as the placenta-specific ABC transporter and as the breast cancer resistance protein (3, 4) , is a ''half transporter'' that most likely functions as a homodimer or higher form oligomer (5, 6) and can efflux a variety of anticancer drugs, including mitoxantrone, doxorubicin, topotecan, and SN-38 (7 -9) . ABCG2 overexpression has been reported in drug-selected carcinoma cell lines (10, 11) , and it is also ubiquitously expressed in a variety of stem cells (12, 13) . Whereas no clinical trials have yet shown a drug resistance role for ABCG2 in cancer patients (14) , inhibitors of ABCG2 have been shown to enhance the efficacy of drugs in mouse preclinical and human clinical trials (15, 16) .
Strategies used to circumvent or resolve the reduced drug accumulation conferred by these polyspecific efflux transporters has relied heavily on the development of clinical inhibitors of P-glycoprotein for concurrent administration with chemotherapeutics (17) . Although a number of these agents have shown promise in vitro, they have not been successful in clinical trials, probably due to interference with the function of endogenous P-glycoprotein and suboptimal trial design (18) . As a result of this, alternative strategies are required to resolve this clinical issue.
Recently, the small molecule thiosemicarbazone NSC73306 was shown to possess a unique property that exploits P-glycoprotein expression and function to induce toxicity (19, 20) while not itself being a substrate for P-glycoprotein (19, 20) . As such, NSC73306 represents a novel strategy to combat MDR in cancer therapy by selectively killing P-glycoprotein -expressing drug resistant carcinoma cells, and it is currently undergoing preclinical evaluation in mouse tumor xenografts alone and in combination with conventional chemotherapeutics, such as doxorubicin.
Due to the fact that the molecular target of NSC73306 is normally associated with drug resistance, it is imperative that its interactions with other drug efflux transporters be explored as part of its preclinical evaluation. Given the overlapping substrate specificity between P-glycoprotein, ABCG2, and to some extent with ABCC1 (16), we have investigated the effect of NSC73306 on transport mediated by a selected group of ABCC subfamily members and on ABCG2-mediated transport. Spontaneous mutations in drug-selected cells at amino acid position 482 (from arginine in the wild-type to glycine or threonine in the mutant ABCG2) were shown to have a vital role in both substrate and inhibitor specificity for ABCG2 (21 -25) . Therefore, both wild-type and mutant ABCG2-overexpressing cells are used to study ABCG2-mediated transport in this study. We observed that NSC73306 does not interact with ABCC1, ABCC4, or ABCC5. However, we show that NSC73306 is transported by ABCG2 in short-term assays, such as 
Cell Lines
The human large -cell lung tumor line COR-L23/P and its doxorubicin-selected MRP1-overexpressing variant COR-L23/R were cultured in RPMI 1640 (Life Technologies, Invitrogen), supplemented with 10% FCS and 100 units of penicillin/streptomycin/mL (Invitrogen) at 37jC in 5% CO 2 humidified air. Doxorubicin (0.2 Ag/mL) was added to the COR-L23R cell culture medium (26) . Parental expressing human embryonic kidney 293 (HEK293) cells, MRP4-expressing HEK293/4.63 cells, and MRP5-expressing HEK293/5I (27, 28) were maintained in DMEM (Life Technologies, Invitrogen), supplemented with 10% FCS and 100 units of penicillin/streptomycin/mL at 37jC in 5% CO 2 humidified air. G418 (80 Ag/mL) was added to the MRP1-HEK293 cell culture medium (29) . HEK293 cells stably transfected with either empty pcDNA3.1 vector (pcDNA-HEK293) or pcDNA3.1 containing ABCG2 coding arginine 482 (R482-HEK293) were cultured in Eagle's MEM (Life Technologies, Invitrogen), supplemented with 10% FCS, 100 units of penicillin/streptomycin/mL, and 2 mg/mL G418 at 37jC in 5% CO 2 humidified air (25) . MCF-7 cells and sublines were maintained in DMEM supplemented with 10% FCS and penicillin/streptomycin. MCF-7 AdVP3000 (T482-ABCG2) cells were maintained in the presence of 3 Ag/mL doxorubicin and 5 Ag/mL verapamil, and MCF-7 FLV1000 (R482-ABCG2) cells were cultured in the presence of 1 Ag/mL flavopiridol (22, 30) . The human colon carcinoma cell line S1 and its drugresistant subline S1-M1-80 were maintained in RPMI supplemented with 10% FCS and 100 units of penicillin/ streptomycin/mL. S1-M1-80 was cultured in 80 Amol/L of mitoxantrone as described previously (8) .
Cytotoxicity Assay Cell Counting Kit-8 assays were used to determine the sensitivities of cells to tested chemicals as described previously (31) . Briefly, cells were plated at a density of 2,000 to 3,000 cells per well in 100 AL of culture medium into 96-well plates at 37jC for 24 h before adding drugs to make a final volume of 200 AL. Cells were incubated for an additional 72 h with various concentrations of drugs. Cell Counting Kit-8 reagent was then added into each well and incubated for 2 to 4 h before reading at a wavelength of 450 nm. IC 50 values were calculated from fitted doseresponse curves obtained from at least three independent experiments.
Fluorescent Drug Accumulation Assay Efflux assays were carried out using a FACSort flow cytometer equipped with Cell Quest software (Becton Dickinson) as described previously (32, 33) . Fluorescent substrates mitoxantrone and calcein were used to study ABCG2-mediated and MRP1-mediated efflux, respectively. Briefly, cells were harvested after trypsinization by centrifugation at 500Âg and then resuspended in Iscove's modified Dulbecco's medium (Life Technologies, Invitrogen) supplemented with 5% FCS. Mitoxantrone (5 Amol/L) or calcein-AM (0.25 Amol/L) was added to 3 Â 10 5 cells in 4 mL of Iscove's modified Dulbecco's medium in the presence or absence of NSC73306 or fumitremorgin C (FTC), the ABCG2-specific inhibitor, or MK-571, an inhibitor of MRP1. In the MRP1 efflux study, the cells were incubated in a 37jC water bath in the dark for 10 min, whereas for the ABCG2 efflux, cells were preloaded for 5 min and followed by 45-min incubation at 37jC in the dark before being pelleted by centrifugation at 500Âg. The cell pellet was then suspended in 300 AL PBS containing 0.1% FCS and analyzed immediately by flow cytometry.
[ Crude membranes (50 Ag/mL) made from the MCF-7 FLV1000 cells were incubated with varying concentrations of NSC73306 for 10 min at room temperature in 50 mmol/L Tris-HCl (pH 7.5), and then 3 to 6 nmol/L [ 125 I]iodoarylazidoprazosin (2,200 Ci/mmol) was added. The samples were incubated for an additional 5 min under subdued light. The samples were exposed to a UV lamp (365 nm) for 10 min at room temperature. The labeled ABCG2 was immunoprecipitated using the BXP-21 antibody and processed as described previously (34) .
Photoaffinity Labeling of ABCG2 with [A-
Crude membranes from MCF-7 FLV1000 cells were incubated with 25 Amol/L or 50 Amol/L of NSC73306 or 10 mmol/L ATP for 10 min at 4jC in ATPase assay buffer.
[a-
32 P]8-azidoATP (10 Amol/L, 10 ACi/nmol) was added under subdued light and incubated for an additional 5 min at 4jC. The samples were then illuminated with a UV lamp (365 nm) for 10 min and were separated on a SDS -7% Tris -acetate polyacrylamide gel at constant voltage. The gel was dried under vacuum and was exposed to an X-ray film for 1 to 3 days at À70jC and exposed to Bio-Max MR film at À80jC for 12 to 24 h.
ATPase Assays ATPase activities of ABCG2 in High Five insect cell crude membranes were measured by end-point inorganic phosphate assay as described previously (35, 36) . ABCG2-specific ATPase activity was recorded as beryllium fluoride -sensitive ATPase activity. Briefly, the assay measured the amount of inorganic phosphate released over 20 min at 37jC in the ATPase assay buffer [50 mmol/L MES-Tris (pH 6.8), 50 mmol/L KCl, 5 mmol/L NaN 3 , 1 mmol/L EGTA, 1 mmol/L ouabain, 2 mmol/L DTT, and 10 mmol/L MgCl 2 ] in the absence and presence of 2.5 mmol/L NaF and 0.2 mmol/L beryllium sulfate. The reaction was initiated by the addition of 5 mmol/L ATP and terminated with SDS (final concentration, 2.5%). The amount of inorganic phosphate released was quantified using a colorimetric method (35) .
Western Blot Analysis Crude membrane protein was prepared and subjected to electrophoresis on a 7.5% SDS-polyacrylamide gel and transferred onto a nitrocellulose membrane as described previously (30) . Each blot was then incubated in blocking buffer {5% (w/v) milk powder in 0.1% TBS-Tween [25 mmol/L Tris-HCl (pH 7.4), 150 mmol/L NaCl, 0.1% Tween 20]} for an hour before the addition of the ABCG2-specific primary antibody (BXP-21, 1: 500 dilution) or anti -glyceraldehyde-3-phosphate dehydrogenase primary antibody (1:2,000 dilution). The secondary antibody used was the horseradish peroxidase -conjugated goat anti-mouse IgG (1:10,000 dilution). Signals were detected using an enhanced chemiluminescence kit (GE Healthcare).
Statistical Analysis Data are mean values F SD from at least three independent experiments. Differences between any mean values were analyzed by two-sided Student's t test, and results were considered statistically significant at P < 0.05. To investigate whether NSC73306 is specifically toxic to cells that overexpress ABC transporters linked to MDR other than P-glycoprotein, the intrinsic cytotoxicity of NSC73306 in cells overexpressing the ABC transporters, such as P-glycoprotein, MRP1, MRP4, MRP5, and ABCG2, were evaluated (Table 1) . To eliminate the possible variability among cell lines, multiple MRP1-overexpressing and ABCG2-overexpressing cell lines were used in this study. ABCG2-expressing HEK (R482-HEK293) cells, human breast carcinoma (MCF7-AdVP3000 and MCF7-FLV1000) cells, and human colon carcinoma (S1-M1-80) cells were used to study ABCG2 function. MRP1-expressing HEK293 cells (MRP1-HEK293) and human large -cell lung tumor (COR-L23/R) cells were used to evaluate MRP1 function. MRP4-expressing and MRP5-expressing HEK293 cells (HEK293/4.63 and HEK293/5I) were used to study MRP4-mediated and MRP5-mediated drug sensitivity, respectively. P-glycoprotein -expressing MCF-7 (MCF7-ADR) cells were used to confirm the effect of NSC73306 on P-glycoprotein -overexpressing cells as described previously (19) . The expression levels of each ABC transporter in respective cell lines was confirmed by Western blot analysis (data not shown) as detailed in Materials and Methods.
The resistance factor (RF) was used to compare the relative toxicity of NSC73306 to cells overexpressing To determine if nontoxic concentrations (0.5 Amol/L) of NSC73306 can resensitize drug resistant cells to chemotherapeutics, drug resistance mediated by ABCG2, MRP1, MRP4, and MRP5 was evaluated. At this concentration, NSC73306 was able to restore sensitivity of ABCG2-overexpressing cells to mitoxantrone and topotecan, which are both well-established ABCG2 substrates with relative RFs of 24 and 14, respectively (30, 37) . The relative RF was calculated by dividing the IC 50 value of drug resistant cells by the IC 50 value of the respective parental cells in the presence of a particular drug. NSC73306 significantly restored the sensitivity of ABCG2-expressing cells to mitoxantrone and topotecan by f6-fold and 3-fold, respectively ( Table 2) . As a positive control, a high dose (5 Amol/L) of FTC was used to show complete reversal of ABCG2-mediated drug resistance.
In contrast, NSC73306 was not able to restore drug sensitivity in cells overexpressing MRP1, MRP4, or MRP5 (Table 2 ). For instance, the presence of NSC73306 was unable to overcome MRP1-mediated etoposide resistance, MRP4-mediated NSC251820 resistance, or MRP5-mediated ZD1694 resistance. Etoposide, NSC251820, and ZD1694 are established substrates of MRP1, MRP4, and MRP5, with relative RFs of 140, 7, and 7, respectively (27, 38, 39) . MK-571 (25 Amol/L) and/or quercetin (10 Amol/L) were used as positive controls to reverse drug resistance conferred by MRPs (39) .
NSC73306 Inhibits the Efflux of Mitoxantrone from both Wild-type and Mutant ABCG2-Expressing Cells
Considering the significant effect of NSC73306 to resensitize ABCG2-overexpressing cells to both mitoxantrone and topotecan, we evaluated the capability of NSC73306 to block ABCG2-mediated mitoxantrone efflux. Using flow cytometry with wild-type R482-HEK293 cells Fig. 1, top) , ABCG2-expressing MCF-7 FLV1000 cells, and ABCG2 mutant R482T MCF-7 AdVp3000 cells (Fig. 1,  bottom) , the intensities of the accumulated fluorescent substrates were then analyzed as described in Materials and Methods. The presence of NSC73306 significantly increased the accumulation of mitoxantrone in both wildtype and mutant ABCG2-expressing cells, whereas it had no effect on the control parental cells (Fig. 1 ). Five and 10 Amol/L of NSC73306 were shown to have the maximum inhibitory effect in ABCG2-overexpressing HEK293 (Fig. 1,  top) and MCF7 cells (Fig. 1, bottom) , respectively. As a positive control, a high concentration of an ABCG2 inhibitor FTC (20 Amol/L) was used to achieve complete block on ABCG2-mediated efflux. Interestingly, it seems that NSC73306 was more effective in blocking the efflux of mitoxantrone from the wild-type 482R (MCF-7 FLV1000) than the mutant 482T (MCF-7 AdVp3000) ABCG2-overexpressing cells (Fig. 1, bottom) . However, mutant 482T cells only exist in in vitro drug-selected cell culture conditions (22) . In addition, the effect of NSC73306 on MRP1-mediated calcein efflux was also evaluated. As expected based on the cytotoxicity studies, NSC73306 had no significant effect on MRP1-mediated calcein efflux, whereas the MRP1 inhibitor MK-571 effectively blocked the MRP1-mediated calcein efflux ( Fig. 1; Supplementary  data Fig. 2A) , which is almost 20-fold more effective than FTC (IC 50 % 5.7 Amol/L; Fig. 2B ). Moreover, the photoaffinity ATP analogue [a-
32 P]8-azidoATP has been shown to bind specifically to the nucleotide-binding domains of numerous ABC transporters (33, 36) , and thus, it was used to test whether NSC73306 interacts with the nucleotide-binding site of ABCG2. Even at high concentrations of 25 and 50 Amol/L (Fig. 2C, lanes 2 and 3) , NSC73306 had no effect on the photolabeling of ABCG2 with [a-32 P]8-azidoATP (Fig. 2C, lane 1) . Excess ATP (10 mmol/L) was used as a positive control to show the displacement of [a- 32 P]8-azido-ATP (Fig. 2C, lane 4) . Collectively, these results suggest that NSC73306 binds specifically to the ABCG2 substrate-binding site(s), but not to the nucleotide-binding sites.
The (Fig. 3, open squares) was significantly higher (f4-fold higher) than in the ABCG2-overexpressing 1 Supplementary material for this article is available at Molecular Cancer Therapeutics Online (http://mct.aacrjournals.org/). 
NSC73306 Is a Dual Modulator of ABCB1 and ABCG2
MCF-7 FLV1000 cells (open circles), whereas the level of accumulation remained constant after f5 min. Moreover, the rate and the total accumulation of [ 3 H]NSC73306 in MCF-7 and MCF-7 FLV1000 cells are identical in the presence of the known ABCG2 inhibitor FTC, 10 Amol/L (filled symbols) or if the assays were carried out at 4jC (data not shown).
NSC73306 Stimulates ABCG2 ATPase Activity The effect of NSC73306 on ABCG2-mediated ATP hydrolysis was examined using High Five insect cells overexpressing ABCG2. NSC73306 stimulates beryllium fluoride -sensitive basal ABCG2 ATPase activity in a concentration-dependent manner with maximum stimulation of 3-fold with the concentration required for 50% stimulation in the range of 140 to 150 nmol/L (n = 3; Fig. 4A ), which is significantly lower than FTC, with the apparent K i of %1.0 Amol/L (40). In comparison, the ABCG2 substrate mitoxantrone also stimulated ABCG2 ATPase activity in a concentration-dependent manner but only to f2-fold of the basal level with the concentration required for 50% stimulation at 12.3 Amol/L (Fig. 4B) . Moreover, increasing concentrations of mitoxantrone (up to 20 Amol/L) had no significant effect on NSC73306 (0.2 Amol/L) -stimulated ABCG2 ATPase activity (Fig. 4B) . In contrast to mitoxantrone, the presence of another known ABCG2 substrate pheophorbide A (up to 20 Amol/L) and ABCG2 inhibitor FTC (up to 5 Amol/L) inhibited NSC73306-stimulated ATP hydrolysis significantly in a concentration-dependent manner, with respective IC 50 values of f1.31 and 0.55 Amol/L (Fig. 4C and D) . Pheophorbide A itself has a biphasic effect on ABCG2 ATPase activity, stimulating ATP hydrolysis at lower concentrations but inhibiting ATP hydrolysis at higher concentrations (Fig. 4C) . The effect of several ABCG2 modulators and substrates, such as curcumin I, XR9576, GF120918, flavopiridol, and nifedipine, on NSC73306-stimulated ABCG2 ATP hydrolysis was also tested (Fig. 4D) . FTC itself inhibits ABCG2 ATP hydrolysis (41), whereas curcumin I (41) and nifedipine (34) stimulate it. XR9576, GF120918, and flavopiridol stimulate ABCG2 ATP hydrolysis with 3-fold, 4-fold, and 2-fold maximum stimulation (data not shown). Despite stimulating ABCG2 ATP hydrolysis, XR9576, GF120918, flavopiridol, and nifedipine failed to have any significant effect on the NSC73306-stimulated ABCG2 ATPase activity. Interestingly, the presence of curcumin I actually further stimulates ABCG2 ATP hydrolysis slightly (Fig. 4D) . Moreover, NSC73306 failed to stimulate either beryllium fluoride -sensitive basal MRP1 or MRP4 ATPase activity as expected ( Fig. 2; Supplementary data) . 1 
Discussion
Thiosemicarbazone-related compounds are well-known to have active antiviral, antibacterial, antimalarial, and antihypertensive properties (42) , as well as antitumor activity that can overcome resistance to chemotherapeutics (19, 43) . Recently, we reported that the small-molecule thiosemicarbazone NSC73306 is significantly more cytotoxic to cells that overexpress P-glycoprotein than to cells that do not, and this unique property is directly proportional to functional P-glycoprotein protein expression (19) . Therefore, we proposed that NSC73306 could be used to resensitize P-glycoprotein -expressing multidrug resistant carcinoma cells to chemotherapy. However, in addition to P-glycoprotein, the presence of MRPs and ABCG2 is well documented in numerous types of the cancer cells (4) and has been shown to play a major role in the development of MDR in cancer cells (16, 18, 44, 45) . For example, ABCG2 and MRP1 are known to transport numerous anticancer chemotherapeutics, whereas MRP4 and MRP5 can transport cyclic nucleotides, as well as prostaglandins, glutathione-conjugated molecules, and various antiviral drugs (16, 21, 44, 46) . This prompted us to investigate the potential interactions of NSC73306 with ABCG2, MRP1, MRP4, and MRP5 and the effect of their expression in cell lines on the cytotoxicity of NSC73306.
Although NSC73306 was more cytotoxic to P-glycoprotein -overexpressing cells (RF = 0.17; ref. 19) , this selective cytotoxic property of NSC73306 was absent in selected cell lines that overexpress ABCG2, MRP1, MRP4, or MRP5 (Table 1) . We did observe that some cell lines are naturally more resistant to NSC73306. It is not unusual for a particular drug to display varying levels of toxicity in cell lines originating from different tissues (41) , but in this instance, intrinsic P-glycoprotein levels in the different cell lines may be responsible for differential cytotoxicity. Low levels of MDR1 mRNA are present in HEK293 cells, which are more NSC73306 sensitive (NSC73306 IC 50 = 7.29 Amol/L), but NSC73306. Despite the lack of selective intrinsic cytotoxicity toward ABCG2-expressing cells, NSC73306 is able to resensitize these cells to both mitoxantrone and topotecan (Table 2 ). This chemosensitizing effect is absent in cells overexpressing MRP1, MRP4, or MRP5. We next showed that NSC73306 not only binds to the substrate-binding site(s) of ABCG2 selectively (Fig. 2) , but is also transported by ABCG2 (Fig. 3) . ATPase assays showed that NSC73306 elicited a 3-fold stimulation of ABCG2-mediated ATP hydrolysis (Fig. 4) , confirming the interaction between NSC73306 and ABCG2; ATP hydrolysis and substrate transport are closely linked events in ABC transporters (47) . It is important to note that NSC73306 has much higher affinity for ABCG2 when compared with the known inhibitor FTC (Figs. 2  and 4 ). In addition, NSC73306 has no effect on the beryllium fluoride-sensitive MRP1 or MRP4 ATPase activity ( Fig. 2 ; Supplementary data), 1 confirming the lack of interaction between NSC73306 and the tested MRPs.
Our results suggest that different ABCG2 modulators have different effects on the NSC73306-stimulated ABCG2 ATPase activity (Fig. 4) . The ABCG2 substrate mitoxantrone has no effect on NSC73306-stimulated ABCG2 ATPase activity (Fig. 4B) . In contrast, NSC73306-stimulated ABCG2 ATPase activity is abolished by increasing concentrations of the ABCG2 substrate pheophorbide A (Fig. 4C ) and the ACBG2 inhibitor FTC (Fig. 4D ). This suggests that both pheophorbide A and FTC compete with and displace NSC73306 at the ABCG2 substrate-binding site(s), hence eliminating the stimulated ABCG2 ATPase activity. Although mitoxantrone, curcumin I, XR9576, GF120918, flavopiridol, and nifedipine all stimulate ABCG2 ATPase activity by themselves, they have no effect on NSC73306-stimulated ABCG2 ATPase activity (Fig. 4D) , either because they bind to an ABCG2 drug-binding site(s) distinct from that of NSC73306 or because they have a lower binding affinity for the same site as NSC73306. Our results are consistent with a recent report by Clark et al. (48) that suggested the presence of at least two drug-binding sites on ABCG2, with possible allosteric communication between them. Crude membranes of ABCG2 baculovirus-infected High Five insect cells (100 Ag/mL protein) were incubated at 37jC for 5 min with the indicated compound or 0.2 Amol/L NSC73306 plus a given concentration of indicated compound in the presence and absence of BeFx. The reaction was initiated by addition of 5 mmol/L ATP and terminated with SDS (final concentration, 2.5%) after 20 min of incubation at 37jC. The amount of inorganic phosphate released was quantitated using a colorimetric method (36) . Points, mean from at least three independent experiments; bars, SE.
The transport data reported here support the notion that reduced accumulation in MCF-7 FLV1000 cells was caused by ABCG2-mediated efflux of [ 3 H]NSC73306 (Fig. 3) . A known transport substrate of ABCG2, [
125 I]iodoarylazidoprazosin (34) , was used in our assay to confirm that functional ABCG2 is present in MCF-7 FLV1000 cells. ABCG2-mediated [
125 I]iodoarylazidoprazosin transport was reduced by both FTC and NSC73306, suggesting that [ 125 I]iodoarylazidoprazosin, FTC, and NSC73306 all bind in the same substrate-binding pocket of ABCG2 (data not shown). Despite NSC73306 being a transported substrate of ABCG2, this transporter does not confer resistance to it in either HEK293 or MCF-7 cells (Table 1) . There are several possible explanations that can produce this result. One possibility is that, in long-term assays, such as the cytotoxicity assay (72 h drug incubation), it may be a metabolite of NSC73306 (including metal complexes, such as iron and copper; ref. 49) , which is not an ABCG2 substrate that confers cytotoxicity. Alternatively, NSC73306 insensitivity to lowered cellular accumulation may be due to NSC73306 interacting with an extracellular target. We have shown previously that growing P-glycoprotein expressing KB-V1 cells in the presence of NSC73306 results in the loss of P-glycoprotein expression and consequently the loss of the MDR phenotype (19) . In contrast, we found no change in ABCG2 mRNA levels, ABCG2 protein surface expression, or its function after growing ABCG2-overexpressing MCF7-FLV1000 cells in 20 Amol/L NSC73306 for as long as 21 days (data not shown).
In summary, the cytotoxic action of NSC73306 requires the functional expression of P-glycoprotein. Although it is not a substrate or modulator for some of the ABCC (ABCC1, ABCC4, and ABCC5) transporters implicated in conferring MDR, this compound interacts with ABCG2 with high affinity and it is transported by this transporter. It has been shown previously that long-term incubation of NSC73306 with P-glycoprotein -expressing cells results in the reduced expression of P-glycoprotein (19) , resensitizing them to conventional chemotherapeutics. Furthermore, NSC73306 can reduce ABCG2-mediated drug efflux of other agents, even at very low concentrations, thus sensitizing ABCG2-expressing cancer cells to chemotherapeutics and also selectively killing P-glycoproteinexpressing multidrug resistant cancer cells. Further work with a mouse model system will provide insight into the suitability of NSC73306 as an agent that can circumvent MDR in cancer cells by inhibiting ABCG2 function and by killing ABCB1-expressing cells.
